Krause Frieder, Wilke Jan, Niederer Daniel, Vogt Lutz, Banzer Winfried
Department of Sports Medicine, Institute of Sport Science, Goethe University Frankfurt, Ginnheimer Landstraße 39, 60487, Frankfurt am Main, Germany.
Trials. 2017 Mar 9;18(1):114. doi: 10.1186/s13063-017-1866-y.
Self-myofascial release (SMR) aims to mimic the effects of manual therapy and tackle dysfunctions of the skeletal muscle and connective tissue. It has been shown to induce improvements in flexibility, but the underlying mechanisms are still poorly understood. In addition to neuronal mechanisms, improved flexibility may be driven by acute morphological adaptations, such as a reduction in passive tissue stiffness or improved movement between fascial layers. The aim of the intended study is to evaluate the acute effects of SMR on the passive tissue stiffness of the anterior thigh muscles and the sliding properties of the associated fasciae.
In a crossover study design, 16 participants will receive all of the following interventions in a permutated random order: (1) one session of 2 × 60 s of SMR at the anterior thigh, (2) one session of 2 × 60 s of passive static stretching of the anterior thigh and (3) no intervention. Passive tissue stiffness, connective tissue sliding, angle of first stretch sensation, as well as maximal active and passive knee flexion angle, will be evaluated before and directly after each intervention.
The results of the intended study will allow a better understanding of, and provide further evidence on, the local effects of SMR techniques and the underlying mechanisms for flexibility improvements.
ClinicalTrials.gov, identifier: NCT02919527 . Registered on 27 September 2016.
自我肌筋膜放松(SMR)旨在模拟手法治疗的效果,解决骨骼肌和结缔组织的功能障碍。研究表明,它能改善柔韧性,但其潜在机制仍知之甚少。除了神经机制外,柔韧性的改善可能还受到急性形态学适应的驱动,如被动组织僵硬度的降低或筋膜层间运动的改善。本研究的目的是评估SMR对大腿前侧肌肉被动组织僵硬度及相关筋膜滑动特性的急性影响。
在一项交叉研究设计中,16名参与者将按随机排列顺序接受以下所有干预措施:(1)在大腿前侧进行1次2×60秒的SMR;(2)在大腿前侧进行1次2×60秒的被动静态拉伸;(3)不进行干预。在每次干预前及干预后立即评估被动组织僵硬度、结缔组织滑动、首次拉伸感觉角度以及最大主动和被动膝关节屈曲角度。
本研究结果将有助于更好地理解SMR技术的局部效应及其改善柔韧性的潜在机制,并提供进一步的证据。
ClinicalTrials.gov,标识符:NCT02919527。于2016年9月27日注册。